Analytical Data
-
Gene name
Staphylokinase
-
简介
Staphylokinase Protein efficiently converts plasminogen into active plasmin, a key enzyme in fibrinolysis. It forms a 1:1 complex with plasmin, activating additional plasminogen molecules and amplifying the fibrinolytic cascade. Staphylokinase Protein, S. aureus is the recombinant Staphylococcus aureus-derived Staphylokinase protein, expressed by E. coli , with tag free.
- Application
-
Alternative Names
Staphylokinase; Neutral proteinase; Protease III; SakSTAR; sak
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P68802
-
Expression Region
S28-K163
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
15.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Staphylokinase (SAK) is a secreted protein produced by Staphylococcus aureus, known for its ability to activate plasminogen, converting it into plasmin, which subsequently leads to fibrinolysis. This characteristic positions SAK as a potential therapeutic agent for treating thrombotic disorders. The recombinant production of SAK has gained significant attention due to the increasing prevalence of antibiotic-resistant Staphylococcus aureus strains, necessitating alternative approaches for treatment. By employing recombinant DNA technology, researchers have successfully expressed SAK in various host systems, enhancing its yield and facilitating its purification for therapeutic use. Furthermore, studies have investigated the structure-function relationship of SAK, revealing insights into its mechanism of action and potential modifications to improve its efficacy and stability as a drug candidate. Overall, the exploration of recombinant Staphylokinase not only highlights the innovative applications of biotechnology in medicine but also underscores the need for continued research into effective treatments for cardiovascular diseases and other conditions associated with abnormal clot formation.
